Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.3 USD | -0.44% |
|
-3.64% | -18.39% |
Jul. 01 | HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study | MT |
Jul. 01 | HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.39% | 82.96B | |
+55.34% | 809B | |
+39.31% | 624B | |
-7.60% | 351B | |
+6.26% | 289B | |
+13.21% | 240B | |
+13.74% | 220B | |
-0.49% | 219B | |
+7.61% | 166B | |
-3.33% | 157B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Insider Sold Shares Worth $400,017, According to a Recent SEC Filing